oral semaglutide formulation Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Oral Semaglutide Administration and Metabolism
Description
They expect patients to try older weight loss meds or structured diet and exercise programs first, before covering newer GLP 1 medications
What if I feel pain during injection
While usually harmless, chronic coldness can occasionally signal anemia, thyroid issues, or inadequate caloric intake
Additionally, depression is associated with a 36.8% increase in coronary heart disease and a 32.9% increase in stroke risk among patients with diabetes [27]
